bioRxivBioinformaticsPreprint
The promoter mutation paucity as part of the dark matter of the cancer genome
Nicholas Allen Baclig AbadiD, Irina GlasiD, Chen HongiD, Annika Small, Yoann PageaudiD, Ana Rita R. MaiaiD, Dieter WeichenhaniD, Christoph PlassiD, Barbara HutteriD, Benedikt BrorsiD, Cindy KörneriD, Lars FeuerbachiD
Abstract
Cancer is a heterogeneous disease caused by genetic alterations. Computational analysis of cancer genomes led to the expansion of the catalog of driver mutations. While individual high-impact mutations have been discovered also in gene promoters, frequency-based approaches have only characterized a few novel candidates. To investigate the promoter mutation paucity in cancer, we developed the REMIND-Cancer workflow to predict activating promoter mutations in silico, irrespective of their recurrence frequency, and applied it to the PCAWG dataset. We positively validated 7 candidates by luciferase assay including mutations within the promoters of ANKRD53 and MYB. Our analysis indicates that particular mutational signatures and necessary co-alterations constrain the creation and positive selection of functional promoter mutations. We conclude that activating promoter mutations are more frequent in the PCAWG dataset than previously observed, which has potential implications for personalized oncology.
- organism: human
- assay: whole-genome sequencing
- research focus: differential expression
- research focus: variant calling
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identifying, Prioritizing, and Visualizing Functional Promoter SNVs with the Recurrence-agnostic REMIND-Cancer Pipeline and pSNV Hunter
Nicholas Allen Baclig Abad, Irina Glas, … Lars Feuerbach·bioRxiv·Sep 10, 2024
- Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences
Sushant Kumar, Jonathan Warrell, … Mark Gerstein·bioRxiv·Mar 12, 2018
- Discovery and characterization of coding and non-coding driver mutations in more than 2,500 whole cancer genomes
Esther Rheinbay, Morten Muhlig Nielsen, … Gad A. Getz·bioRxiv·Dec 23, 2017
- Identification of (ultra-)rare functional promoter mutations in cancer using sequence-based deep learning models
Tijs van Lieshout, Carlos G. Urzúa-Traslaviña, … Lude Franke·medRxiv·May 6, 2025
- In silico saturation mutagenesis of cancer genes
F. Muinos, F. Martinez-Jimenez, … N. Lopez-Bigas·bioRxiv·Jun 3, 2020
- Finding Driver Mutations in Cancer: Elucidating the Role of Background Mutational Processes
A.-L. Brown, M. Li, … A. R. Panchenko·bioRxiv·Apr 1, 2019